Lucentis (Ranibizumab Vials) 10mg/ml 0.23ml/2.3mg

Lucentis (Ranibizumab) 10mg/ml 0.23ml/2.3mg vials are prescribed for eye conditions like wet age-related macular degeneration. This anti-VEGF therapy helps maintain vision clarity. Store at 2-8°C to preserve potency. Always handle with sterile technique.

Strength

10mg/ml 0.23ml/2.3mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Novartis Pharma Stein AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Lucentis (Ranibizumab) is used to treat serious eye conditions caused by abnormal blood vessel growth. It helps reduce swelling and leakage in the retina, supporting vision maintenance for adults. Commonly prescribed for wet age-related macular degeneration and diabetic macular edema. Patients often ask what Lucentis is used for in eye care settings.

Side Effects

After Lucentis treatment, many patients report improved clarity in their vision over time. The medication works by targeting specific proteins to slow abnormal blood vessel growth in the eye. Some may notice reduced eye discomfort or swelling following administration. Effects vary by individual and condition severity.

Precautions & Warnings

Lucentis requires careful handling to prevent contamination or infection. Always use sterile equipment and follow aseptic techniques during preparation. Store vials refrigerated between 2-8°C and protect from light. Discard any unused portion as directed by healthcare guidelines.

Avoid Interactions

Lucentis is an injectable therapy that may interact with other eye medications or treatments. Always inform your healthcare provider about all current medications before starting Lucentis. No specific drug interactions are widely reported, but concurrent eye treatments should be coordinated carefully.

References

Frequently Asked Questions

Lucentis is prescribed for conditions like wet age-related macular degeneration and diabetic macular edema to help maintain vision clarity.

Lucentis is given as an injection into the eye by a healthcare professional following sterile procedures.

No, Lucentis vials must be refrigerated between 2-8°C to maintain effectiveness.

Lucentis is the brand name for Ranibizumab, an anti-VEGF therapy used in ophthalmology.

Unused portions of Lucentis should be discarded according to healthcare guidelines to prevent contamination.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.